KOSDAQBiotech & Pharma386380

Sky Labs

₩18,140▼ 2.99%2026-10-02 close

Market Cap

₩338.1B

Turnover

₩11.8B

Volume

640,000 shares

Shares out.

18.8M

PER

—

PBR

—

EPS

—

Dividend Yield

—

PER, PBR and dividend yield are calculated from the latest confirmed results (EPS, BPS, dividend per share) and the current share price · Prices as of the 2026-10-02 close

Report overview

Blood Pressure Ring: Profitability Is the Next Hurdle

Skylabs has commercialized the world's first ring-type cuffless continuous blood pressure monitor—achieving full penetration of Korea's five major hospital groups and EU CE-MDR certification—but three structural challenges remain: a near-total revenue concentration in a single distributor, a widening operating loss structure, and an unfinished FDA clinical pathway, all set against a backdrop of extreme post-IPO price volatility.

1
World's first ring-type cuffless continuous BP monitor with simultaneous Korean MFDS approval and health insurance reimbursement; first ever specifically recommended in the 2026 Korean Hypertension Society clinical guidelines
2
Revenue surged from KRW 590 mn (2023) → KRW 4.09 bn (2024) → KRW 7.94 bn (2025); gross profit turned positive for the first time in 2025 (KRW 3.91 bn) but operating loss widened to KRW 14.73 bn
3
Approximately 98% of domestic hospital revenue flows through Daewoong Pharmaceutical; overseas revenue reached a 52% share in 2026 H1, reflecting incremental channel diversification
4
FDA clinical trial formally initiated, targeting completion in H1 2027; regulatory approvals from Korean MFDS, EU CE-MDR, and UK MHRA already secured across three major markets
5
Strategic partnerships with Omron Ventures (CVC investment, Nov 2025), Omron Healthcare, Otsuka Pharmaceutical, and Kakao Healthcare; stock surged 2.35x the IPO price of KRW 10,000 within two trading days, with a turnover of KRW 1.7 trillion on Day 2

Business structure

Skylabs, founded in September 2015, is a digital healthcare company whose core business encompasses ring-type wearable medical devices based on photoplethysmography (PPG) sensing technology and an AI-driven medical data production platform.

The company highlights a vertically integrated R&D capability, having developed its own AI algorithms for PPG signal analysis, ring-type hardware, and medical data integration software entirely in-house without external technology licensing.

The flagship product, CART BP pro, enables continuous 24-hour blood pressure monitoring via a ring worn on the finger—without any arm cuff—and is reported to be the world's first wearable cuffless blood pressure device to simultaneously hold Korean MFDS approval and health insurance reimbursement coverage.

As of June 2026, it had been adopted by all five of Korea's major hospital groups (Big 5), 38 of 47 tertiary care hospitals, and over 1,800 hospitals and clinics nationwide; in May 2026, the Korean Society of Hypertension's 2026 clinical guidelines became the first in the world to specifically recommend the device for out-of-office blood pressure monitoring.

The product portfolio extends beyond CART BP pro to include CART ON for in-hospital patient monitoring, CART BP for consumers, CART O2 for oxygen saturation, and CART VITAL for multi-vital signs; the company is also developing CART NET, a medical data production platform for pharmaceutical clinical trials and medical AI applications.

Domestic distribution is handled exclusively through Daewoong Pharmaceutical's hospital network, resulting in approximately 98% of domestic revenue being concentrated in that single channel across 2023–2025.

Overseas distribution relies on Omron Healthcare (approximately 50% global market share in blood pressure monitors) and Japan's Otsuka Pharmaceutical for Europe and Japan, while Kakao Healthcare signed a CART BP consumer supply contract in October 2025; Omron Ventures made a strategic investment in November 2025.

In terms of competitive positioning, while several global electronics and medical device manufacturers have developed cuffless blood pressure solutions with regulatory approval, the CART BP pro is reportedly the only ring-type product to hold both formal medical device approval and insurance reimbursement backed by published clinical evidence.

The adoption of CART BP pro in the government-led Korea National Institute of Health's KoGES large-scale cohort study serves as an early reference case for the data platform business.

Recent trends

Skylabs listed on the KOSDAQ on September 4, 2026, following a subdued IPO process: the institutional book-building ratio was 63.41:1 and the retail subscription ratio was just 2.85:1, among the weakest in the 2026 KOSDAQ IPO cohort.

The IPO was priced at KRW 10,000—23.1% below the lower end of the KRW 13,000–16,000 target range—and total proceeds were reduced from KRW 26–32 billion to KRW 20 billion.

On Day 1 (September 4), the stock opened at KRW 8,330 (−16.7% below IPO price) before recovering intraday; by Day 2 (September 5), the share price reached KRW 23,500 (+135% day-on-day) with a turnover of KRW 1.7 trillion—more than three times the approximately KRW 440 billion market cap in a single session.

In terms of operating performance, revenue grew rapidly from KRW 590 million in 2023 to KRW 4.09 billion in 2024 and KRW 7.94 billion in 2025.

In 2025, gross profit turned positive for the first time (KRW 3.91 billion), but the operating loss widened to KRW 14.73 billion from KRW 11.73 billion in 2024 due to heavy SG&A.

In 2026 H1, revenue was KRW 4.9 billion and operating loss was KRW 9.2 billion (net loss KRW 9.5 billion); revenue improved from the year-earlier period (KRW 4.0 billion) but operating losses also widened from KRW 6.1 billion.

Overseas revenue reached KRW 2.6 billion in 2026 H1, surpassing domestic revenue (KRW 2.3 billion) for the first time at a 52% share.

Balance sheet metrics remain relatively sound—debt-to-equity ratio of 25.4%, current ratio of 432.1%, and debt-to-asset ratio of 2.39% as of 2026 H1—but cash and cash equivalents declined from KRW 20.41 billion at end-2025 to KRW 13.76 billion at end-Q1 2026, a decrease of over KRW 6.6 billion in three months, warranting monitoring of the cash-burn trajectory.

Outlook

In its securities registration statement, Skylabs projected revenues of KRW 10.2 billion in 2026, KRW 18.8 billion in 2027, and KRW 38.7 billion in 2028, with an operating breakeven target in 2028; the company noted that contributions from CART O2, CART VITAL, and CART NET are not yet embedded in these forecasts, though actual results will depend on regulatory timelines, overseas market reception, and product launch execution.

For the US market, Skylabs has completed the FDA Q-Submission consultation and is moving into IRB review and patient enrollment, targeting clinical completion in H1 2027 and FDA clearance by year-end 2027.

Known reimbursement rates for 24-hour ABPM testing are substantially higher overseas than in Korea (approximately KRW 18,000): roughly KRW 65,000 in the US, KRW 67,000 in Italy, and up to KRW 218,000 at UK hospital settings, indicating meaningful per-unit revenue upside if FDA and broader international approvals are obtained.

In Europe, pharmacy-based ABPM programs are expanding rapidly in the UK and Italy, and Skylabs' CE-MDR certification and Omron distribution partnership provide a foundation to participate in that market growth.

Net IPO proceeds of approximately KRW 19.9 billion are earmarked for R&D headcount, clinical trials, and global business development; the gap between the current pace of cash consumption and the 2028 breakeven timeline is the central financial variable to monitor.

According to Korean hypertension prescription data, the prescription volume rate for CART BP pro rose 53.7% over a twelve-month period through mid-2026, indicating sustained domestic market uptake.

Bull factors

World-Unique Regulatory and Reimbursement Moat

CART BP pro is reported to be the world's only ring-type cuffless blood pressure monitor to hold both Korean MFDS medical device approval and health insurance reimbursement simultaneously.

Its first-ever specific recommendation in the 2026 Korean Hypertension Society clinical guidelines represents formal clinical endorsement from the medical establishment.

This foundation has driven channel coverage across all five major Korean hospital groups, 38 tertiary care hospitals, and over 1,800 clinics nationwide; given the time and capital required to replicate both regulatory approval and published clinical evidence, the barrier to entry for late-stage competitors is materially high.

High Overseas Reimbursement Rates and Global Partnerships

The reimbursement rate for 24-hour ABPM in Korea is approximately KRW 18,000, compared to roughly KRW 65,000 in the US, KRW 67,000 in Italy, and up to KRW 218,000 at UK hospitals, implying substantially higher revenue per test in overseas markets.

Overseas revenue already surpassed domestic in 2026 H1 (KRW 2.6 billion vs. KRW 2.3 billion, 52% share), demonstrating that global demand is translating into actual sales.

Omron Ventures' strategic investment (November 2025), a partnership with Omron Healthcare (approximately 50% global BP monitor market share), and an exclusive Japan distribution agreement with Otsuka Pharmaceutical collectively reinforce the global distribution infrastructure.

The rapid expansion of pharmacy-based ABPM programs in the UK and Italy provides concrete, ongoing evidence of new market formation in Europe.

Medical Data Platform Optionality

As CART BP pro deployment grows, Skylabs' CART NET platform is designed to accumulate clinically validated continuous blood pressure data monetizable through pharmaceutical clinical trials and medical AI.

The adoption of CART BP pro in the government-led Korea National Institute of Health's KoGES rural aging in-depth study provides an early reference case for the research and data platform business.

At the 2025 Digital Biomarkers in Clinical Trials Summit in Basel, attended by over 350 participants from firms including Roche and Novartis, Skylabs presented the clinical trial utility of CART BP pro—a concrete signal of the long-term strategic direction. However, the timeline for material revenue from the data platform business remains uncertain at this stage.

Bear factors

Near-Total Revenue Concentration in Daewoong

With domestic hospital distribution entirely delegated to Daewoong Pharmaceutical, the channel accounted for 98.4%, 99.2%, and 98.2% of total revenue in 2023, 2024, and 2025, respectively.

Although end-customers are dispersed across hospitals and clinics, Daewoong's pricing decisions, contract terms, and order volumes directly affect when Skylabs recognizes revenue and collects cash.

At end-2025, accounts receivable from Daewoong constituted 99.1% of total receivables, and the accounts receivable turnover ratio declined from 4.84x in 2024 to 2.09x in Q1 2026, signaling a slowdown in cash conversion.

The pace at which diversification via CART ON (hospital ward monitoring), CART BP (B2C), and international partnerships converts into meaningful independent revenue is the key variable for mitigating this concentration risk.

Persistent Operating Losses and Accelerating Cash Burn

Despite gross profit turning positive in 2025 (KRW 3.91 billion), operating losses widened to KRW 14.73 billion, and Q1 2026 SG&A (KRW 5.69 billion) was 2.7 times the quarterly revenue level.

In 2026 H1, the operating loss was KRW 9.2 billion—worse than the KRW 6.1 billion in the year-earlier period—and net loss was KRW 9.5 billion.

Cash and cash equivalents fell by over KRW 6.6 billion in just one quarter, from KRW 20.41 billion at end-2025 to KRW 13.76 billion at end-Q1 2026; whether the combined available cash (including approximately KRW 19.9 billion in IPO proceeds) is sufficient to sustain operations through to the 2028 breakeven depends heavily on how quickly new revenue streams materialize.

The 2028 operating profit target implicitly requires the simultaneous fulfillment of multiple conditions: new product commercialization, FDA clearance, and a sharp overseas revenue ramp.

Weak IPO Reception and Lock-up Expiration Overhang

The institutional book-building ratio of 63.41:1 and the retail subscription ratio of 2.85:1 were among the lowest in the 2026 KOSDAQ IPO cohort; 60.11% of institutional order volume was submitted below the lower end of the target range, resulting in a 23.1% discount to the floor price.

Total proceeds were reduced from KRW 26–32 billion to KRW 20 billion, and the R&D headcount budget was trimmed from KRW 12.8 billion to KRW 8.6 billion.

Only approximately 27.26% of total shares were freely tradeable at listing, and the securities registration statement identifies successive lock-up expirations as a potential source of additional supply pressure on the share price.

The conservative stance taken by both institutional and retail investors at the IPO stage indicates a wide divergence in market participants' views on fair value, juxtaposed with the extreme post-listing price volatility.

Risk factors

FDA Clinical Delay & Regulatory Risk

The US FDA clinical trial targets completion in H1 2027 and regulatory clearance by year-end 2027, but protocol amendments, patient recruitment difficulties, or tightened regulatory standards could delay the schedule.

Failure to obtain or a material delay in FDA clearance would directly impair the medium-to-long-term revenue growth trajectory presented in the company's own projections.

Medical device regulatory frameworks vary significantly by market, and further tightening in key overseas jurisdictions or extended administrative processing timelines could slow global expansion relative to plan.

Even after obtaining foreign regulatory approvals, securing local health insurance coverage and physician adoption typically requires additional time.

Competitive Pressure and Technological Displacement

Global electronics and medical device conglomerates and emerging digital health startups continue to invest in cuffless blood pressure measurement technology. If smartwatch-type wearables achieve BP measurement accuracy that meets clinical thresholds, structural changes in the wearable BP monitor market could emerge.

Skylabs' current differentiation rests on clinical evidence and regulatory approval, but if competitors obtain equivalent approvals and clinical data, competition on price, brand, and distribution will intensify.

Given the rapid pace of advances in AI algorithms and sensor technology, the risk of core technology obsolescence is an ongoing consideration.

Liquidity and Additional Financing Risk

While the IPO generated net proceeds of approximately KRW 19.9 billion, the ongoing combination of operating losses and expenditures on R&D, clinical trials, and global business development makes liquidity management a central concern.

If the 2028 operating breakeven target is not met, additional financing may be required, potentially leading to equity dilution through new share issuance.

Rising interest rates, increased market volatility, or a deterioration in risk sentiment could raise financing costs or suppress investor appetite for growth capital, slowing execution of the business plan. Foreign exchange risk also accompanies the company's expanding overseas operations.

Overall view

Skylabs holds a differentiated position within the digital healthcare sector by virtue of having commercialized the world's first and only ring-type cuffless continuous blood pressure monitor, achieving full penetration of Korea's Big 5 hospital groups, obtaining health insurance reimbursement, securing EU CE-MDR certification, and being specifically recommended in the 2026 Korean Hypertension Society clinical guidelines.

At the same time, the company faces clear structural challenges: domestic revenue concentration of over 98% in a single distributor, a widening operating loss profile, and an FDA clinical pathway yet to be completed.

The post-listing price surge to 2.35x the IPO price within two trading days—accompanied by a KRW 1.7 trillion turnover—stands in sharp contrast to the subdued IPO demand, reflecting the supply-demand and momentum dynamics typical of small-cap newly listed stocks.

Over the medium term, the key milestones to watch are domestic prescription growth acceleration through 2026–2027, material overseas revenue contributions from distribution partnerships, and FDA clinical trial progress.

The pace of reducing Daewoong concentration and the commercialization progress of new products (CART ON, CART NET, etc.) will determine whether the 2028 breakeven target is achievable; the pace of cash burn and the schedule of lock-up expirations are near-term supply variables requiring ongoing monitoring.

This report is for informational purposes only, based on publicly available disclosure and media information, and does not constitute an investment recommendation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 15 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.